Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...

Royalty Pharma has signed a deal to pay Biogen $250m to support the development of its late-stage experimental lupus ...

The agreement hands Biogen as much as $250 million in exchange for milestone payments and sales royalties for litifilimab, ...

The funding agreement comes as Biogen revealed a modest Q4 sales beat, which analysts expect will be “overshadowed” by the ...

Biogen has entered a collaboration with Stoke Therapeutics to develop and commercialise zorevunersen to treat Dravet syndrome ...

Royalty Pharma is giving Biogen $250 million for its lupus treatment litifilimab, which is currently in Phase 3 development ...

The deal, which features up to $385 million in milestones, gives Biogen exclusive rights to commercialize Stoke’s ...

Biogen posted strong Q4 results, surpassing estimates, while forecasting a 2025 revenue decline. The company secured up to ...

We are excited to collaborate with Biogen on litifilimab,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “Royalty Pharma offers tailored, win-win funding solutions for ...

Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...